The results showed that the Psoriasis Area Severity Index score was decreased in psoriasis patients treated with immune modulatory oligonucleotide- (IMO-) 3100, an antagonist of TLR7 and TLR9 [141]. The gene discussed is TLR9; the disease is psoriasis.